mAbxience - Single-Use Bioreactor Sites Technology

GH Genhelix, S.A. is currently carrying out its strategic plan for the development of Bevacizumab biosimilar (monoclonal antibody), which is partially financed by the Instituto de Competitividad Empresarial de la Junta de Castilla y León with the financial support of the European Union.